BioArctic AB (BRCTF) reports significant licensing deals and growing market demand, while navigating regulatory challenges and increased expenses.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
5d
Barchart on MSNStocks Find Support From Strong Earnings ResultsFord Motor (F) is down more than -6% after CFO House warned that profit may fall by $2 billion ... Camden Property Trust (CPT), CMS Energy Corp (CMS), ConocoPhillips (COP), Eli Lilly & Co (LLY), ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...
BioArctic, with a current market capitalization of $158.45 million, reported a robust performance for the fourth quarter of 2024, achieving net revenues of $101 million, with a significant increase in ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...
It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results